CNS is a small biotech company. The founder of the firm is deciding if it is worth applying for phase I approval which will allow the company to continue its research.
He must determine the value of the research. Using the conventional DCF valuation method, he's not sure if this captures the research’s total value. He must choose between either the Black Scholes or binomial model in order to determine the worth more correctly.
Publication Date: 03/04/2004
This is just an excerpt. This case is about Finance
Related Case Solutions & Analyses:
D2Hawkeye: Growing the Medical IT Enterprise
AXMONY
Forest of Flowers
Chaparral Steel (Abridged)
2012 Fuel Hedging at JetBlue Airways
Nodal Logistics And Custo Brasil
An Old Bank in a New Country: Restructuring Nile Commercial Bank of South Sudan
Gold as a Portfolio Diversifier: The World Gold Council and Investing in Gold
James and Laura
Netflix: Valuing a New Business Model
